Monitoring Blood Pressure in Patients at Risk of Dementia

1. Introduction: Blood Pressure Control as a Modifiable Dementia Risk Factor

Dementia affects more than 55 million people worldwide, and this figure is projected to nearly triple by 2050. Despite the scale of the problem, disease-modifying treatments remain limited. Attention has therefore shifted toward prevention - and hypertension has emerged as one of the most significant and modifiable risk factors for dementia, including both Alzheimer’s disease and vascular dementia.

The evidence is compelling: longitudinal studies consistently demonstrate that elevated blood pressure (BP) in midlife is associated with a substantially increased risk of late-life cognitive decline and dementia. The association is not confined to sustained hypertension; blood pressure variability, loss of nocturnal dipping, and episodes of both hypotension and hypertension each contribute independently to cerebrovascular injury and neurodegeneration.

Yet in routine clinical practice, BP monitoring in patients at cognitive risk remains reactive rather than proactive. Single office measurements, taken infrequently and under conditions that introduce significant measurement error, provide an incomplete picture of a patient’s haemodynamic profile. They cannot capture the diurnal fluctuations, nocturnal patterns, and visit-to-visit variability that are most predictive of brain health outcomes.

For clinicians managing older adults, patients with established cardiovascular risk factors, or individuals with early signs of cognitive change, structured and longitudinal BP monitoring is not an adjunct to care - it is a clinical imperative. This article outlines who requires closer monitoring, what to measure and how, the specific challenges posed by older and frailer patients, and how BP data can be integrated meaningfully into a cognitive risk management framework.

2. Who Is at Risk? Identifying Patients Who Require Closer Monitoring

Not all patients carry equal risk of hypertension-mediated cognitive decline. Identifying those who warrant a more structured and intensive BP monitoring approach requires consideration of several overlapping risk domains.

Midlife Hypertension

The relationship between hypertension and dementia risk is strongly time-dependent. Elevated systolic BP in midlife (broadly defined as ages 40–65) is among the most robust modifiable predictors of late-life dementia, with a risk increase of approximately 60% compared to normotensive peers. Critically, this association appears to attenuate or even reverse in very late life, reflecting the complex haemodynamic changes associated with advanced ageing and frailty. Patients who enter their sixties with a history of poorly controlled hypertension should be considered at elevated baseline risk, regardless of their current BP status.

Comorbidities That Amplify Vascular Brain Risk

Several comorbid conditions compound the effect of hypertension on the brain and should prompt enhanced monitoring:

• Atrial fibrillation (AFib): Associated with cerebral hypoperfusion, microemboli, and silent infarcts. The combination of AFib and hypertension substantially increases the risk of both overt stroke and progressive vascular cognitive impairment.

• Type 2 diabetes: Independently associated with accelerated cognitive decline through microvascular, inflammatory, and metabolic mechanisms. Diabetic patients with coexisting hypertension face a compounded risk profile.

• Chronic kidney disease (CKD): Closely linked to hypertension and associated with increased cerebrovascular risk. CKD also complicates BP management targets and increases the likelihood of both hypertensive peaks and hypotensive episodes.

• Prior stroke or TIA: Established cerebrovascular disease significantly reduces cognitive reserve. In this group, even modest BP fluctuations may have clinically meaningful consequences for remaining brain function.

• Obstructive sleep apnoea (OSA): Drives nocturnal hypertension and non-dipping BP patterns, contributing directly to white matter lesion accumulation and cognitive impairment.

Lifestyle and Genetic Risk Factors

Beyond established comorbidities, several additional factors should inform the clinical decision to institute closer BP monitoring:

• Family history of early-onset dementia or cardiovascular disease

• Obesity and metabolic syndrome, which amplify hypertensive end-organ damage

• Heavy alcohol use and smoking, both of which accelerate cerebrovascular ageing

• Low educational attainment and limited cognitive reserve, which reduce the threshold at which haemodynamic injury manifests clinically

• Subjective cognitive complaints or borderline performance on screening instruments, even in the absence of a formal diagnosis

3. What to Monitor: Beyond Office Blood Pressure

Office BP measurement remains the entry point for hypertension diagnosis and management. However, in patients at elevated dementia risk, it represents the floor rather than the ceiling of what should be assessed. Out-of-office measurement modalities provide substantially richer clinical information and are now endorsed by all major hypertension guidelines.

Home Blood Pressure Monitoring (HBPM)

HBPM is the most scalable and patient-accessible method for capturing longitudinal BP data. When performed using a standardised protocol - duplicate readings in the morning and evening, over seven consecutive days, with the first day discarded - it yields a reliable dataset that is more reproducible than office measurement and more predictive of cardiovascular outcomes.

In the dementia-risk context, the particular value of HBPM lies in its longitudinal dimension. A single home reading session has limited value; it is the accumulation of readings over weeks, months, and years that enables clinicians to detect trends in mean BP, rising visit-to-visit variability, and gradual loss of the morning-evening differential that may signal deteriorating autonomic regulation. Patients should be encouraged to maintain a consistent monitoring schedule and to bring their complete records to each clinical encounter.

Clinicians should verify that patients are using validated devices (refer to the STRIDE BP registry for an up-to-date list) and have received instruction in correct measurement technique, including appropriate posture, cuff positioning, and rest period prior to measurement.

Ambulatory Blood Pressure Monitoring (ABPM)

ABPM provides a 24-hour BP profile at regular intervals and is the reference standard for characterising diurnal BP patterns. It is particularly indicated in this patient group when:

• Office BP is borderline or inconsistent with home readings (to identify masked hypertension or white-coat effect)

• Non-dipping or reverse-dipping pattern is suspected based on clinical history or sleep complaints

• Orthostatic hypotension is suspected but not reliably captured in the office setting

• There is unexplained cognitive decline in a patient with apparently controlled office BP

Key parameters to review on ABPM in dementia-risk patients include the night-time mean BP, the dipping ratio, the morning surge amplitude, and the 24-hour standard deviation as a measure of short-term variability.

Visit-to-Visit Variability

Serial office or home readings recorded across multiple clinical encounters provide an estimate of visit-to-visit BP variability - a metric with demonstrated independent prognostic value for stroke, white matter lesion burden, and cognitive decline. Calculating the standard deviation (SD) or coefficient of variation (CV) of systolic BP across at least five readings provides a clinically meaningful variability index. Patients with an SD greater than 10–15 mmHg for systolic BP warrant targeted review of their antihypertensive regimen and monitoring intensity, in accordance with current guidelines.

Nocturnal Dipping

Loss of the normal nocturnal BP dip (defined as a 10–20% reduction in mean nocturnal versus daytime BP) is independently associated with white matter lesion accumulation, silent lacunar infarcts, and cognitive impairment. Non-dipping and reverse-dipping patterns are not detectable through office measurement alone and require ABPM for identification. In patients at elevated dementia risk, nocturnal dipping status should be considered a routine component of the initial haemodynamic assessment.

4. Age-Specific Challenges in BP Monitoring

Older adults present several physiological and clinical characteristics that complicate both the measurement and interpretation of blood pressure. Clinicians must account for these factors to avoid both undertreatment and iatrogenic harm.

Orthostatic Hypotension

Orthostatic hypotension (OH) - defined as a sustained reduction in systolic BP of at least 20 mmHg or diastolic BP of at least 10 mmHg within three minutes of standing - is common in older adults, affecting up to 30% of those aged 70 and over. It results from impaired baroreflex sensitivity, reduced venous return, and autonomic dysfunction, all of which are more prevalent in the context of neurodegeneration.

OH is clinically significant in the dementia-risk population for several reasons:

• It is associated with an approximately twofold increased risk of dementia, independent of supine BP levels

• It contributes to cerebral hypoperfusion, particularly in patients with impaired autoregulation

• It increases fall risk, which in cognitively impaired patients carries disproportionate consequences

• It may be exacerbated by antihypertensive therapy, necessitating careful titration and regular reassessment

Routine measurement of standing BP - at one and three minutes after standing - should be incorporated into the standard BP assessment protocol for all patients aged 65 and over, or younger patients with known autonomic dysfunction, Parkinson’s disease, or diabetes.

White-Coat Effect in Elderly Patients

The white-coat effect - a transient elevation in BP triggered by the clinical encounter - is more pronounced and more variable in older adults. It can lead to overestimation of true mean BP, unnecessary intensification of antihypertensive therapy, and consequent risk of iatrogenic hypotension. Conversely, masked hypertension - where office BP appears controlled but home or ambulatory readings reveal persistent elevation - is also more common in this group and is associated with worse cardiovascular and cognitive outcomes than sustained hypertension.

HBPM or ABPM should be used to confirm the diagnosis of hypertension and to guide treatment decisions in older adults, rather than relying on office measurements alone. Discordance between office and out-of-office readings of 10 mmHg or more warrants further investigation.

Frailty and the J-Curve Concern

In frail older adults, the relationship between BP and adverse outcomes follows a J-shaped curve: both high and low BP are associated with increased mortality and cognitive decline. Aggressive BP lowering in this population risks cerebral hypoperfusion, falls, syncope, and acute kidney injury.

Frailty status should be formally assessed - using a validated instrument such as the Clinical Frailty Scale (CFS) or the Fried Frailty Phenotype - before establishing BP targets and monitoring intensity. In frail patients:

• BP targets should be individualised and generally less aggressive than those applied to robust older adults

• Systolic BP below 120 mmHg may be harmful and warrants review of the antihypertensive regimen

• Monitoring should include standing BP at every encounter to detect treatment-induced orthostatic hypotension

• Clinical judgement should integrate BP trends with functional status, symptom burden, and patient preference

5. Integrating BP Monitoring into Cognitive Risk Management

Effective use of BP monitoring in the dementia-risk population requires more than data collection - it requires a structured framework for interpretation, action thresholds, and integration with broader cognitive assessment.

Monitoring Cadence

The appropriate frequency of BP monitoring should be risk-stratified:

• High-risk patients (midlife hypertension history, AFib, prior stroke/TIA, or cognitive complaints): Standardised HBPM protocol at every clinical review, with ABPM annually or following any medication change. Cognitive screening at least annually.

• Moderate-risk patients (well-controlled hypertension with one or more comorbidities): HBPM protocol every three to six months. ABPM if home readings show increasing variability or loss of diurnal pattern. Cognitive screening every one to two years.

• Lower-risk patients (treated hypertension, no comorbidities, stable cognitive status): Routine HBPM as per standard hypertension management guidelines. Cognitive screening as clinically indicated.

Action Thresholds

In the absence of dementia-specific BP targets in current guidelines, clinicians should apply standard hypertension thresholds while remaining attentive to the additional indicators that are particularly relevant in this population:

• Mean home systolic BP consistently above 135 mmHg: review antihypertensive regimen in accordance with current 2023 ESH / 2024 ESC guidance

• Visit-to-visit systolic SD above 10–15 mmHg: review medication adherence, timing, and formulation; consider ABPM

• Non-dipping ratio below 0.9 on ABPM: assess for OSA, review evening antihypertensive dosing

• Orthostatic drop of 20 mmHg or more in systolic BP: review antihypertensive load, assess hydration and autonomic function, refer to specialist if recurrent

• Unexplained decline in cognitive screening score alongside BP changes: prompt multidisciplinary review

Cross-Referencing BP Trends with Cognitive Screening

Longitudinal BP data has its greatest clinical utility when reviewed in parallel with cognitive assessment results. Several validated screening instruments are in routine use:

• Montreal Cognitive Assessment (MoCA): Sensitive to mild cognitive impairment; score below 26 warrants further evaluation. Serial MoCA scores tracked alongside BP trends can reveal temporal correlations between haemodynamic deterioration and cognitive change.

• Mini-Mental State Examination (MMSE): Widely used but less sensitive to early or subtle deficits; more appropriate for monitoring established cognitive impairment over time.

• General Practitioner Assessment of Cognition (GPCOG) and Mini-Cog: Brief instruments suited to primary care settings; useful for flagging patients who warrant more detailed assessment.

When a patient shows a decline in cognitive screening performance, reviewing their BP record for concurrent changes - rising variability, loss of dipping, or new orthostatic pattern - can help distinguish vascular from non-vascular contributions to cognitive change and inform referral decisions. Documenting both BP trends and cognitive screening scores in a structured format at each encounter facilitates this longitudinal perspective.

Where electronic health records permit, flagging patients as ‘at elevated dementia risk’ and linking their BP monitoring records to their cognitive assessment history supports more consistent and proactive management across clinical encounters and care settings.

6. Conclusion

Blood pressure is the most consistently modifiable risk factor for dementia identified to date. Yet its management in patients at cognitive risk too often defaults to reactive treatment of overt hypertension, without the structured longitudinal monitoring needed to detect the subtler haemodynamic patterns - rising variability, non-dipping, orthostatic instability - that are most damaging to the ageing brain.

Key practice points for clinicians:

• Stratify patients by dementia risk and establish a monitoring cadence appropriate to that risk level, rather than applying a one-size-fits-all approach.

• Move beyond office BP measurement: HBPM and ABPM provide the longitudinal and diurnal data that single clinic readings cannot deliver.

• Assess standing BP routinely in patients aged 65 and over, and in all patients on antihypertensive therapy with comorbidities associated with autonomic dysfunction.

• Account for frailty when setting BP targets and interpreting monitoring data; aggressive lowering in frail patients carries its own cognitive and functional risks.

• Integrate BP monitoring records with cognitive screening results at each clinical encounter to enable early detection of vascular contributions to cognitive change.

Establishing a structured home BP monitoring protocol for all patients at elevated dementia risk is among the highest-yield interventions available in this space. Consistent readings over time, captured with validated devices and reviewed longitudinally, provide the depth of haemodynamic data required to detect concerning patterns before they translate into irreversible brain injury.

Omron Healthcare offers a range of clinically validated home blood pressure monitors designed to support this approach, enabling healthcare professionals to build the longitudinal BP records that underpin effective cognitive risk management. For clinicians seeking to deepen their knowledge in this area, the OMRON Academy offers a dedicated course on Hypertension & Dementia, available at academy.omron-healthcare.com.

Approval Code: OHEAPP-1176